ECSP088545A - Composición para prevenir o tratar daños de la mucosa en los conductos gastrointestinales - Google Patents

Composición para prevenir o tratar daños de la mucosa en los conductos gastrointestinales

Info

Publication number
ECSP088545A
ECSP088545A EC2008008545A ECSP088545A ECSP088545A EC SP088545 A ECSP088545 A EC SP088545A EC 2008008545 A EC2008008545 A EC 2008008545A EC SP088545 A ECSP088545 A EC SP088545A EC SP088545 A ECSP088545 A EC SP088545A
Authority
EC
Ecuador
Prior art keywords
composition
prevent
gastrointestinal
mucosa damage
damage
Prior art date
Application number
EC2008008545A
Other languages
English (en)
Inventor
Ki-Baik Hahm
Dong-Kyu Kim
Mi-Sun Kwak
Sang-Aun Joo
Byoung-Seok Moon
Geun-Seog Song
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of ECSP088545A publication Critical patent/ECSP088545A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se provee una composición para prevenir o tratar daños de la mucosa en los conductos gastrointestinales, que incluye el revaprazán o una sal del mismo y un portador farmacéuticamente aceptable. El revaprazán o su sal tienen un excelente efecto preventivo o de tratamiento para daños a la mucosa gastrointestinal, al potenciar un factor defensivo en la mucosa gastrointestinal, y simultáneamente actuar como un antagonista de la bomba de ácido..
EC2008008545A 2005-12-01 2008-06-13 Composición para prevenir o tratar daños de la mucosa en los conductos gastrointestinales ECSP088545A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20050116567 2005-12-01

Publications (1)

Publication Number Publication Date
ECSP088545A true ECSP088545A (es) 2008-08-29

Family

ID=38092428

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008545A ECSP088545A (es) 2005-12-01 2008-06-13 Composición para prevenir o tratar daños de la mucosa en los conductos gastrointestinales

Country Status (15)

Country Link
US (1) US7776873B2 (es)
EP (1) EP1954279A4 (es)
JP (1) JP5207974B2 (es)
KR (1) KR100805660B1 (es)
CN (2) CN102309490A (es)
AU (1) AU2006321471B2 (es)
BR (1) BRPI0619081A2 (es)
CA (1) CA2631068C (es)
CR (1) CR10018A (es)
EC (1) ECSP088545A (es)
HK (1) HK1123507A1 (es)
IL (1) IL191680A0 (es)
MY (1) MY145406A (es)
WO (1) WO2007064128A1 (es)
ZA (1) ZA200805747B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10835541B2 (en) 2015-07-30 2020-11-17 Takeda Pharmaceutical Company Limited Tablet

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2673536A1 (en) * 2006-12-22 2008-07-03 Yuhan Corporation Revaprazan-containing solid dispersion and process for the preparation thereof
CN102470126A (zh) 2009-07-09 2012-05-23 拉夸里亚创药株式会社 用于治疗与异常肠胃运动有关的疾病的酸泵拮抗剂
KR101730865B1 (ko) * 2011-02-11 2017-04-27 주식회사유한양행 레바프라잔-함유 나노입자를 포함하는 경구투여용 약학 조성물 및 그의 제조방법
KR101739818B1 (ko) * 2011-05-20 2017-05-26 주식회사유한양행 레바프라잔 또는 그의 염을 함유하는 현탁액 형태의 경구투여용 약학 조성물
CN105998688A (zh) * 2016-06-22 2016-10-12 郑亮 一种胃粘膜损伤的抑制方法
KR20180107341A (ko) * 2017-03-16 2018-10-02 차의과학대학교 산학협력단 칼륨 경쟁적 위산분비억제제를 유효성분을 함유하는 장 누수 증후군 치료 및 예방용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ235877A (en) * 1989-11-02 1992-09-25 Mcneil Ppc Inc Composition comprising acetaminophen or nsaid and an h 1 or h 2 receptor blocker and/or proton pump inhibitor for treating overindulgence
ES2201112T3 (es) * 1994-08-13 2004-03-16 Yuhan Corporation Nuevos derivados de pirimidina y procedimientos para su preparacion.
CA2358479C (en) * 1996-05-04 2004-07-13 Yuhan Corporation 4-substituted-2-(4-fluorophenylamino)-5,6 dimethylpyrimidine
KR20000052775A (ko) * 1996-10-25 2000-08-25 가마쿠라 아키오 신규한 헤테로사이클릭 아미드 화합물 및 의약으로서의 그의 용도
HU226752B1 (en) 1996-10-29 2009-09-28 Yuhan Corp Process for preparation of pyrimidine derivatives
GB0110338D0 (en) * 2001-04-27 2001-06-20 Sb Pharmco Inc Novel processes
US8206741B2 (en) * 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10835541B2 (en) 2015-07-30 2020-11-17 Takeda Pharmaceutical Company Limited Tablet

Also Published As

Publication number Publication date
WO2007064128A1 (en) 2007-06-07
CN101316594B (zh) 2012-07-25
BRPI0619081A2 (pt) 2011-09-20
JP2009517462A (ja) 2009-04-30
JP5207974B2 (ja) 2013-06-12
KR100805660B1 (ko) 2008-02-21
US7776873B2 (en) 2010-08-17
EP1954279A1 (en) 2008-08-13
HK1123507A1 (en) 2009-06-19
CA2631068A1 (en) 2007-06-07
ZA200805747B (en) 2009-11-25
AU2006321471B2 (en) 2010-07-29
US20070129391A1 (en) 2007-06-07
MY145406A (en) 2012-02-15
AU2006321471A1 (en) 2007-06-07
EP1954279A4 (en) 2009-06-03
KR20070057663A (ko) 2007-06-07
CN101316594A (zh) 2008-12-03
IL191680A0 (en) 2009-08-03
CA2631068C (en) 2011-01-11
CN102309490A (zh) 2012-01-11
CR10018A (es) 2008-09-02

Similar Documents

Publication Publication Date Title
ECSP088545A (es) Composición para prevenir o tratar daños de la mucosa en los conductos gastrointestinales
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
CL2012001971A1 (es) Compuestos derivados de 1-piperazinil-3-piridin-carboxilato, como bloqueadores de los canales de sodio dependientes de voltaje; composicion farmaceutica; y su uso para el tratamiento de enfermedades respiratorias o del tracto respiratorio tal como asma, epoc, tos, silicosis, entre otras.
PA8852901A1 (es) Inhibidores de proteina cinasa
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
AR077629A1 (es) Mimetico de smac
AR059575A1 (es) Metodo para el tratamiento de enfermedades inflamatorias
UY31215A1 (es) Compuestos de morfolino pirimidina, procesos para su preparacion, composiciones farmacéuticas conteniéndolos y su uso en terapia.
ECSP12011799A (es) Compuestos de espiropiperidina y uso farmacéutico de los mismos
CO6351785A2 (es) Inhibidores de cinasa map p39
CO6280490A2 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
GT201200164A (es) "nuevos compuestos de espiropiperidina"
CL2008000592A1 (es) Compuestos derivados de pirrol sustituido, supresores de la secrecion de acidos; composicion farmaceutica; y uso en el tratamiento o profilaxis en enfermedades tales como ulcera peptica, gastritis, esofagitis, entre otras.
CR20110339A (es) Compuestos útiles para inhibir chk1
BRPI0709581A8 (pt) compostos de bicicloeteroarila como moduladores de px27 e seu uso
CL2013000713A1 (es) Compuestos pirazin-2-cabonil-imino-1,3,8-triaza-espiro-[4.5]-decan-sustituidos, bloqueadores del canal de sodio epitelial (enac); composicion farmaceutica que los incluye; metodo de prevencion o tratamiento; y su uso para tratar una enfermedad o condicion mediada por el bloqueo del canal de sodio epitelial.
CL2010001361A1 (es) Compuestos derivados de piperidin-carboxamida, inhibidores de renina; composicion farmaceutica que los comprende; y uso en el tratamiento o prevencion de una enfermedad circulatoria, hipertension y/o diversos daños organicos atribuibles a la hipertension.
ECSP10010494A (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasa
GT201200038A (es) Composicion para tratar la fibrosis quistica
AR084216A1 (es) Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit
AR090806A1 (es) Glucosidos de pirazol y su utilizacion en el tratamiento de la diabetes tipo i y ii
AR087902A1 (es) COMPOSICIONES Y METODOS PARA TRATAR EL CANCER USANDO EL INHIBIDOR DE PI3Kb Y EL INHIBIDOR DE LA VIA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF
EA201170821A1 (ru) Энзастаурин для лечения рака